In Italy, the sales of diabetes medicine per capita are projected to increase steadily from $25.4 in 2024 to $27.1 in 2028. This reflects a consistent year-on-year growth, with an annual increase of approximately 2.63% over the forecast period. Compared to the baseline value in 2023, the market shows a promising upward trend driven by increasing diabetes prevalence, improved access to medication, and advancements in treatment options. The Compound Annual Growth Rate (CAGR) over the five-year period suggests a sustainable growth trajectory for diabetes medication sales.
Future trends to watch for include:
- Technological advancements in diabetes treatment.
- Increased adoption of biosimilars and generics.
- Government initiatives to combat diabetes and improve healthcare access.
- Rising awareness and preventive measures leading to altered demand.
